INTRODUCTION: The present study reports on examination of the effects of encapsulating the tyrosine kinase inhibitors (TKIs) vandetanib and lenvatinib into a biomacromolecular ferritin-based delivery system. METHODS: The encapsulation of TKIs was performed via two strategies: i) using an active reversible pH-dependent reassembly of ferritin´s quaternary structure and ii) passive loading of hydrophobic TKIs through the hydrophobic channels at the junctions of ferritin subunits. After encapsulation, ferritins were surface-functionalized with folic acid promoting active-targeting capabilities. RESULTS: The physico-chemical and nanomechanical analyses revealed that despite the comparable encapsulation efficiencies of both protocols, the active loading affects stability and rigidity of ferritins, plausibly due to their imperfect reassembly. Biological experiments with hormone-responsive breast cancer cells (T47-D and MCF-7) confirmed the cytotoxicity of encapsulated and folate-targeted TKIs to folate-receptor positive cancer cells, but only limited cytotoxic effects to healthy breast epithelium. Importantly, the long-term cytotoxic experiments revealed that compared to the pH-dependent encapsulation, the passively-loaded TKIs exert markedly higher anticancer activity, most likely due to undesired influence of harsh acidic environment used for the pH-dependent encapsulation on the TKIs' structural and functional properties. CONCLUSION: Since the passive loading does not require a reassembly step for which acids are needed, the presented investigation serves as a solid basis for future studies focused on encapsulation of small hydrophobic molecules.

Athinoula A Martinos Center for Biomedical Imaging Massachusetts General Hospital Harvard Medical School Charlestown MA USA

Central European Institute of Technology Brno University of Technology Brno Czech Republic

Central European Institute of Technology Masaryk University Brno Czech Republic

Department of Chemistry and Biochemistry Mendel University in Brno Brno Czech Republic

Zobrazit více v PubMed

Mann J. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer. 2002;2(2):143–148. doi:10.1038/nrc723 PubMed DOI

Sawyers C. Targeted cancer therapy. Nature. 2004;432(7015):294–297. doi:10.1038/nature03095 PubMed DOI

Al-Obeidi FA, Lam KS. Development of inhibitors for protein tyrosine kinases. Oncogene. 2000;19(49):5690–5701. doi:10.1038/sj.onc.1203926 PubMed DOI

Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest. 2015;125(5):1780–1789. doi:10.1172/JCI76094 PubMed DOI PMC

Caldemeyer L, Dugan M, Edwards J, Akard L. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep. 2016;11(2):71–79. doi:10.1007/s11899-016-0309-2 PubMed DOI

Herbrink M, Nuijen B, Schellens JHM, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev. 2015;41(5):412–422. doi:10.1016/j.ctrv.2015.03.005 PubMed DOI

Zhang JM, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28–39. doi:10.1038/nrc2559 PubMed DOI

Haringhuizen A, van Tinteren H, Vaessen HFR, Baas P, van Zandwijk N. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Ann Oncol. 2004;15(5):786–792. doi:10.1093/annonc/mdh177 PubMed DOI

Wani TA, Bakheit AH, Zargar S, Hamidaddin MA, Darwish IA. Spectrophotometric and molecular modelling studies on in vitro interaction of tyrosine kinase inhibitor linifanib with bovine serum albumin. PLoS One. 2017;12(4):1–12. doi:10.1371/journal.pone.0176015 PubMed DOI PMC

Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011;117(8):75–87. doi:10.1182/blood-2010-07-294330 PubMed DOI

Smidova V, Michalek P, Goliasova Z, et al. Nanomedicine of tyrosine kinase inhibitors. Theranostics. 2020. PubMed PMC

Tesarova B, Musilek K, Rex S, Heger Z. Taking advantage of cellular uptake of ferritin nanocages for targeted drug delivery. J Control Release. 2020;325:176–190. doi:10.1016/j.jconrel.2020.06.026 PubMed DOI

Ebrahimi KH, Bill E, Hagedoorn PL, Hagen WR. The catalytic center of ferritin regulates iron storage via Fe(II)-Fe(III) displacement. Nat Chem Biol. 2012;8(11):941–948. doi:10.1038/nchembio.1071 PubMed DOI

Tosha T, Hasan MR, Theil EC. The ferritin Fe2 site at the diiron catalytic center controls the reaction with O2 in the rapid mineralization pathway. Proc Natl Acad Sci U S A. 2008;105(47):18182–18187. doi:10.1073/pnas.0805083105 PubMed DOI PMC

Tesarova B, Dostalova S, Smidova V, et al. Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine. Appl Mater Today. 2020;18:1–10.

Indra R, Cerna T, Heger Z, et al. Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells. Toxicology. 2019;419:40–54. doi:10.1016/j.tox.2019.03.009 PubMed DOI

Tesarova B, Charousova M, Dostalova S, et al. Folic acid-mediated re-shuttling of ferritin receptor specificity towards a selective delivery of highly cytotoxic nickel(II) coordination compounds. Int J Biol Macromol. 2019;126:1099–1111. doi:10.1016/j.ijbiomac.2018.12.128 PubMed DOI

Peskova M, Ilkovics L, Hynek D, et al. Detergent-modified catalytic and enzymomimetic activity of silver and palladium nanoparticles biotemplated by Pyrococcus furiosus ferritin. J Colloid Interface Sci. 2019;537:20–27. doi:10.1016/j.jcis.2018.11.005 PubMed DOI

Pekarik V, Peskova M, Guran R, et al. Visualization of stable ferritin complexes with palladium, rhodium and iridium nanoparticles detected by their catalytic activity in native polyacrylamide gels. Dalton Trans. 2017;46(40):13690–13694. doi:10.1039/C7DT02818K PubMed DOI

Dostalova S, Cerna T, Hynek D, et al. Site-directed conjugation of antibodies to apoferritin nanocarrier for targeted drug delivery to prostate cancer cells. ACS Appl Mater Interfaces. 2016;8(23):14430–14441. PubMed

Dostalova S, Polanska H, Svobodova M, et al. Prostate-specific membrane antigen-targeted site-directed antibody-conjugated apoferritin nanovehicle favorably influences in vivo side effects of doxorubicin. Sci Rep. 2018;8:1–13. PubMed PMC

Heger Z, Skalickova S, Zitka O, Adam V, Kizek R. Apoferritin applications in nanomedicine. Nanomedicine. 2014;9(14):2233–2245. doi:10.2217/nnm.14.119 PubMed DOI

Khattab M, Wang F, Clayton AHA. A pH-induced conformational switch in a tyrosine kinase inhibitor identified by electronic spectroscopy and quantum chemical calculations. Sci Rep. 2017;7:1–10. doi:10.1038/s41598-017-16583-z PubMed DOI PMC

Huang Y, Hu QH, Song GX, et al. Cucurbit 7,8 urils binding to gefitinib and the effect of complex formation on the solubility and dissolution rate of the drug. RSC Adv. 2014;4(7):3348–3354. doi:10.1039/C3RA45017A DOI

Liu XF, Jin WL, Theil EC. Opening protein pores with chaotropes enhances Fe reduction and chelation of Fe from the ferritin biomineral. Proc Natl Acad Sci U S A. 2003;100(7):3653–3658. doi:10.1073/pnas.0636928100 PubMed DOI PMC

Zhen ZP, Tang W, Guo CL, et al. Ferritin nanocages to encapsulate and deliver photosensitizers for efficient photodynamic therapy against cancer. ACS Nano. 2013;7(8):6988–6996. doi:10.1021/nn402199g PubMed DOI PMC

Zhang LB, Li L, Di Penta A, et al. H-chain ferritin: a natural nuclei targeting and bioactive delivery nanovector. Adv Healthc Mater. 2015;4(9):1305–1310. doi:10.1002/adhm.201500226 PubMed DOI

Cabanillas ME, Habra MA. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016;42:47–55. doi:10.1016/j.ctrv.2015.11.003 PubMed DOI

Fernandez M, Javaid F, Chudasama V. Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem Sci. 2018;9(4):790–810. doi:10.1039/C7SC04004K PubMed DOI PMC

Cheung A, Opzoomer J, Ilieva KM, et al. Anti-folate receptor alpha-directed antibody therapies restrict the growth of triple-negative breast cancer. Clin Cancer Res. 2018;24(20):5098–5111. doi:10.1158/1078-0432.CCR-18-0652 PubMed DOI PMC

Necas D, Klapetek P. Gwyddion: an open-source software for SPM data analysis. Cent Eur J Phys. 2012;10(1):181–188.

Crich SG, Cadenazzi M, Lanzardo S, et al. Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells. Nanoscale. 2015;7(15):6527–6533. doi:10.1039/C5NR00352K PubMed DOI

Jiang B, Fang L, Wu KM, Yan XY, Fan KL. Ferritins as natural and artificial nanozymes for theranostics. Theranostics. 2020;10(2):687–706. doi:10.7150/thno.39827 PubMed DOI PMC

Yao HC, Long XF, Cao L, et al. Multifunctional ferritin nanocages for bimodal imaging and targeted delivery of doxorubicin into cancer cells. RSC Adv. 2016;6(111):109322–109333. doi:10.1039/C6RA13845D DOI

Stuhn L, Auernhammer J, Dietz C. pH-depended protein shell dis- and reassembly of ferritin nanoparticles revealed by atomic force microscopy. Sci Rep. 2019;9:1–9. doi:10.1038/s41598-019-53943-3 PubMed DOI PMC

Yang R, Gao YJ, Zhou ZK, Strappe P, Blanchard C. Fabrication and characterization of ferritin-chitosan-lutein shell-core nanocomposites and lutein stability and release evaluation in vitro. RSC Adv. 2016;6(42):35267–35279. doi:10.1039/C6RA04058F DOI

Zang JC, Chen H, Zhao GH, Wang FD, Ren FZ. Ferritin cage for encapsulation and delivery of bioactive nutrients: from structure, property to applications. Crit Rev Food Sci Nutr. 2017;57(17):3673–3683. doi:10.1080/10408398.2016.1149690 PubMed DOI

Takahashi T, Kuyucak S. Functional properties of threefold and fourfold channels in ferritin deduced from electrostatic calculations. Biophys J. 2003;84(4):2256–2263. doi:10.1016/S0006-3495(03)75031-0 PubMed DOI PMC

Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2015;141(5):769–784. doi:10.1007/s00432-014-1767-3 PubMed DOI PMC

Stella B, Arpicco S, Peracchia MT, et al. Design of folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci. 2000;89(11):1452–1464. doi:10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P PubMed DOI

De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3(2):133–149. doi:10.2147/IJN.S596 PubMed DOI PMC

Kim M, Rho Y, Jin KS, et al. pH-dependent structures of ferritin and apoferritin in solution: disassembly and reassembly. Biomacromolecules. 2011;12(5):1629–1640. doi:10.1021/bm200026v PubMed DOI

Reif GA, Wallace DP. ADPKD cell proliferation and Cl−-dependent fluid secretion In: Weimbs T, editor. Methods in Cell Biology. Vol. 153 Academic Press; 2019:69–92. PubMed

de la Harpe KM, Kondiah PPD, Choonara YE, Marimuthu T, Du Toit LC, Pillay V. The hemocompatibility of nanoparticles: a review of cell-nanoparticle interactions and hemostasis. Cells. 2019;8(10):1–25. doi:10.3390/cells8101209 PubMed DOI PMC

Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013;8(2):137–143. doi:10.1038/nnano.2012.237 PubMed DOI

Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: a review in hepatocellular carcinoma. Drugs. 2019;79(6):665–674. doi:10.1007/s40265-019-01116-x PubMed DOI

Colombo C, De Leo S, Di Stefano M, Vannucchi G, Persani L, Fugazzola L. Primary adrenal insufficiency during lenvatinib or vandetanib and improvement of fatigue after cortisone acetate therapy. J Clin Endocrinol Metab. 2019;104(3):779–784. doi:10.1210/jc.2018-01836 PubMed DOI PMC

Zhang C, Zhang A, Hou W, et al. Mimicking pathogenic invasion with the complexes of Au22(SG)18-engineered assemblies and folic acid. ACS Nano. 2018;12(5):4408–4418. doi:10.1021/acsnano.8b00196 PubMed DOI

Hogemann-Savellano D, Bos E, Blondet C, et al. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia. 2003;5(6):495–506. doi:10.1016/S1476-5586(03)80034-9 PubMed DOI PMC

Rho JK, Choi YJ, Lee JK, et al. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol Cancer Res. 2009;7(10):1736–1743. doi:10.1158/1541-7786.MCR-08-0504 PubMed DOI

Yang J, Chen H, Vlahov IR, Cheng JX, Low PS. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci U S A. 2006;103(37):13872–13877. doi:10.1073/pnas.0601455103 PubMed DOI PMC

Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009;13(3):256–262. doi:10.1016/j.cbpa.2009.03.022 PubMed DOI

Yang J, Chen HT, Vlahov IR, Cheng JX, Low PS. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J Pharmacol Exp Ther. 2007;321(2):462–468. doi:10.1124/jpet.106.117648 PubMed DOI

Kidane TZ, Sauble E, Linder MC. Release of iron from ferritin requires lysosomal activity. Am J Physiol Cell Physiol. 2006;291(3):445–455. doi:10.1152/ajpcell.00505.2005 PubMed DOI

Kwok JC, Richardson DR. Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents. Mol Pharmacol. 2004;65(1):181–195. doi:10.1124/mol.65.1.181 PubMed DOI

Li WJ, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies focus on kinase inhibitors. J Am Coll Cardiol. 2015;66(10):1160–1178. doi:10.1016/j.jacc.2015.07.025 PubMed DOI

Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62(24):7284–7290. PubMed

Jeong Y, Bae SY, You D, et al. EGFR is a therapeutic target in hormone receptor-positive breast cancer. Cell Physiol Biochem. 2019;53(5):805–819. PubMed

Mechera R, Soysal SD, Piscuoglio S, et al. Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer. BMC Cancer. 2019;19:1–10. doi:10.1186/s12885-018-5262-0 PubMed DOI PMC

Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14(17):5459–5465. doi:10.1158/1078-0432.CCR-07-5270 PubMed DOI

Nasir A, Holzer TR, Chen M, Man MZ, Schade AE. Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies. Cancer Cell Int. 2017;17:1–12. doi:10.1186/s12935-017-0427-5 PubMed DOI PMC

Goussia A, Simou N, Zagouri F, et al. Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A hellenic cooperative oncology group (HeCOG) trial. PLoS One. 2018;13(7):1–19. doi:10.1371/journal.pone.0200302 PubMed DOI PMC

Nanoformulation of the Broad-Spectrum Hydrophobic Antiviral Vacuolar ATPase Inhibitor Diphyllin in Human Recombinant H-ferritin